• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press Releases Translations

Das Bundesministerium für Bildung und Forschung unterstützt DNDi mit 8 Millionen Euro zur Entwicklung von neuen Behandlungen für vernachlässigte Tropenkrankheiten

Genf, Schweiz — 23 Jan 2012
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Das Bundesministerium für Bildung und Forschung (BMBF) hat der Drugs for Neglected Diseases initiative 8 Millionen Euro bewilligt, um innovative Behandlungen für vernachlässigte Tropenkrankheiten zu entwickeln. Die Finanzierung wird über die Jahre 2011 bis 2015 ausgeschüttet und ist Teil eines mit 20 Millionenen Euro finanzierten Programms, mit dem das BMBF nun drei Produktentwicklungspartnerschaften (PDPs) fördert*.
[English]

Diese Förderung erlaubt es DNDi, die Entwicklung angepasster und auf Patienten in Entwicklungsländern zugeschnittener Medikamente gegen vernachlässigte Tropenkrankheiten (neglected tropical diseases – NTDs) fortzusetzen. Die Forschungsaktivitäten von DNDi reichen dabei von der Molekülsuche bis zur klinischen Forschung für Schlafkrankheit, viszerale Leishmaniose, der Chagas-Krankheit und Helmintheninfektionen.

Schätzungsweise eine Milliarde Menschen – die meisten davon in Entwicklungsländern – sind von einer der 17 vernachlässigten Tropenkrankheiten betroffen, die in fast 150 Ländern und Regionen vorkommen. Trotz der großen medizinischen Fortschritte in den letzten 50 Jahren haben vernachlässigte Tropenkrankheiten bis vor kurzem weder genügend Aufmerksamkeit erfahren, noch ausreichend Investitionen in Forschung und Entwicklung und innerhalb der internationalen Zusammenarbeit erhalten.

„Wir begrüßen dieses langfristige Engagement für Forschung und Entwicklung im Bereich der vernachlässigten Tropenkrankheiten. Diese Unterstützung wird einen signifikanten Unterschied in der Entwicklung neuer Gesundheitstechnologien machen, die für Kontrollprogramme und zur Eliminierung der Krankheiten benötigt werden. Hoffentlich wird dies auch zu einem verstärkten Engagement anderer Regierungen im Kampf gegen vernachlässigte Tropenkrankheiten führen, sagte Dr. Bernard Pécoul Geschäftsführer von DNDi.

Seit seiner Gründung, hat DNDi bereits sechs neue Behandlungen eingeführt: zwei für Malaria, eine für die Schlafkrankheit, eine für viszerale Leischmaniose (VL) in Ost-Afrika und eine für VL in Asien und nun kürzlich ein pädiatrische Formulierung eines Medikaments zur Behandlung von Kindern mit der Chagas-Krankheit. Einige vielversprechende Kandidaten für orale und kürzere Behandlungen befinden sich bereits in der Pipeline des Forschungsportfolios von DNDi. Sie könnten zu einer echten Verbesserung der Behandlung vieler Patienten führen.

„Wir sind fest davon überzeugt, dass die Aktivitäten von DNDi, also die Entwicklung und Einführung  kostengünstiger und einfach anzuwendender Behandlungen, dazu beitragen wird, dass NTDs besser  kontrolliert und sogar eliminiert werden können. Und dies gilt insbesondere für Krankheiten, für die bisher keine geeignete Prävention, Diagnose oder Behandlungt existiert“, erklärte Dr. Helge Braun, Parlamentarischer Staatssekretär im BMBF. „Mit diesem Förderprogramm möchte das BMBF nachhaltig zum Erreichen bestimmter Millenium Development Ziele beitragen, und die Förderung von DNDi wird Teil dieser Anstrengungen sein“, fügte er hinzu.

# # #

Über DNDi

Die Drugs for Neglected Diseases initiative (DNDi) ist eine not-for-profit-Organisation im Bereich Forschung und Entwicklung. Ihr Ziel ist es, neue Therapien für vernachlässigte Krankheiten bereitzustellen – insbesondere für die Schlafkrankheit, die Chagas-Krankheit, Leishmaniose (Kala Azar), bestimmte Helmintheninfektionen (Wurmerkrankungen),  HIV bei Kindern und Malaria. DNDi wurde im Jahr 2003 von Ärzte ohne Grenzen/Médecins sans Frontières, der Oswaldo Cruz Stiftung (FIOCRUZ, Brasilien), dem Indischen Council for Medical Research (ICMR), dem Kenya Medical Research Institute (KEMRI), dem Gesundheitsministerium von Malaysia und dem Institute Pasteur in Frankreich gegründet. Das Special Programme for Tropical Disease (TDR) fungiert als ständiger Beobachter. www.dndi.org

Media contacts

Violaine Dällenbach, Press & Communications Manager, DNDi
Office: +41 22 906 92 47 / mobile: +41 79 424 14 74 / email: vdallenbach@dndi.org

Nina Holzhauer, Advisor Institutional and Donor Relations, DNDi
Office :+49 (0)30 66 40 1169/ mobil : +49 (0)175 15 77 191 / email : nholzhauer@dndi.org

Funding

Read, watch, share

Loading...
Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo